{
    "title": "114_hr5858",
    "content": "The Act may be cited as the \"Research to Accelerate Cures and Equity for Children Act\" or the \"RACE for Children Act\". It requires pediatric assessments. The \"Research to Accelerate Cures and Equity for Children Act\" or the \"RACE for Children Act\" mandates pediatric assessments for cancer drugs targeting molecular targets in pediatric populations. The \"RACE for Children Act\" requires pediatric assessments for cancer drugs targeting molecular targets in pediatric populations, ensuring a meaningful therapeutic benefit over existing therapies. The \"RACE for Children Act\" mandates pediatric assessments for cancer drugs targeting specific molecular targets in pediatric populations to provide additional treatment options. The Act also requires early meetings with applicants to discuss pediatric study plans. The \"RACE for Children Act\" requires early discussions with applicants regarding pediatric study plans for cancer drugs targeting specific molecular targets in pediatric populations. The \"RACE for Children Act\" mandates timely submission of pediatric study plans and discussions on challenges for deferral or waivers under the Federal Food, Drug, and Cosmetic Act. The \"RACE for Children Act\" requires changes to the Federal Food, Drug, and Cosmetic Act regarding meetings, orphan drugs, and guidance from the Secretary of Health and Human Services. The \"RACE for Children Act\" mandates guidance from the Secretary of Health and Human Services on implementing amendments related to pediatric cancer studies and molecular targets. The Act applies to drug applications submitted under specific sections of existing laws 18 months after enactment. Additionally, a report to Congress is required by July 12, 2021. The Secretary of Health and Human Services must report to Congress on the implementation of amendments related to pediatric cancer studies and molecular targets. The Act does not limit the Secretary's authority to issue written requests under section 505A of the Federal Food, Drug, and Cosmetic Act."
}